Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2020 Jun 4;19(8):1598–1612. doi: 10.1158/1535-7163.MCT-20-0106

Figure 1: Clinicopathological characteristics associated with CHD1L expression.

Figure 1:

(A) OS of CHD1L expression in CRC patients, P = 0.0167. (B) OS of CHD1L expression in Stage II/III patient cohort, P = 0.0191. (C) Differential expression of CHD1L in CRC by stage, P = 0.028. (D) Differential expression of CHD1L among N staging in CRC patients, P = 0.013 (N1), 0.05 (N2) relative to N0. (E) Differential expression of CHD1L among CRC molecular subtypes, P < 0.001. (F) Expression of CHD1L between CRC patients with normal and deficient DNA mismatch repair, P < 0.001.